Active TB · HIV‐negative people at risk of TB infection1
It is very uncertain whether rifampicin plus isoniazid changes active TB compared with isoniazid (very low certainty).
1 finding from 1 review
Adherence · HIV‐negative people at risk of TB infection1
Rifampicin plus isoniazid showed no clear difference in adherence compared with isoniazid (high certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
Rifampicin plus isoniazid showed no clear difference in treatment‐limiting adverse events compared with isoniazid (low certainty).
1 finding from 1 review
Hepatotoxicity · HIV‐negative people at risk of TB infection1
Rifampicin plus isoniazid showed no clear difference in hepatotoxicity compared with isoniazid (low certainty).
1 finding from 1 review
Active TB · HIV‐negative people at risk of TB infection1
Rifapentine plus isoniazid weekly showed no clear difference in active TB compared with isoniazid daily (moderate certainty).
1 finding from 1 review
Adherence · HIV‐negative people at risk of TB infection1
Rifapentine plus isoniazid weekly probably leads to higher adherence compared with isoniazid daily (moderate certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
Rifapentine plus isoniazid weekly probably leads to higher treatment‐limiting adverse events compared with isoniazid daily (moderate certainty).
1 finding from 1 review
Hepatotoxicity · HIV‐negative people at risk of TB infection1
Rifapentine plus isoniazid weekly leads to lower hepatotoxicity compared with isoniazid daily (high certainty).
1 finding from 1 review
Active TB · HIV‐positive children not taking ART
Isoniazid prophylaxis may leads to lower active TB compared with placebo (low certainty).
1 finding from 1 review
Death · HIV‐positive children not taking ART
Isoniazid prophylaxis may leads to lower death compared with placebo (low certainty).
1 finding from 1 review
Active TB · Children living with HIV receiving ART
It is very uncertain whether isoniazid prophylaxis changes active TB compared with placebo (very low certainty).
1 finding from 1 review
Death · Children living with HIV receiving ART
It is very uncertain whether isoniazid prophylaxis changes death compared with placebo (very low certainty).
1 finding from 1 review
Clinical failure clinical observation · patients with BCG adverse reactions1
It is very uncertain whether oral Isoniazid (INH) changes clinical failure clinical observation compared with no intervention (very low certainty).
1 finding from 1 review
Clinical failure clinical observation · infants with BCG vaccine adverse reactions1
It is very uncertain whether oral isoniazid plus rifampicin changes clinical failure clinical observation compared with no intervention (very low certainty).
1 finding from 1 review
Time to resolution of acute illness · patients with BCG adverse reactions1
1 finding from 1 review
Intervention not reported
False positivespeople incorrectly classified as having isoniazid resistance · adults with pulmonary tuberculosis irrespective of rifampicin resistance (i.e. whether or not their rifampicin resistance status was…
1 finding from 1 review
Intervention not reported
True positivespeople with isoniazid resistance · adults with pulmonary tuberculosis irrespective of rifampicin resistance (i.e. whether or not their rifampicin resistance status was…
1 finding from 1 review
Intervention not reported
False negativespeople incorrectly classified as not having isoniazid resistance · adults with pulmonary tuberculosis irrespective of rifampicin resistance (i.e. whether or not their rifampicin resistance status was…
1 finding from 1 review
Intervention not reported
True negativespeople without isoniazid resistance · adults with pulmonary tuberculosis irrespective of rifampicin resistance (i.e. whether or not their rifampicin resistance status was…
1 finding from 1 review
Treatment failure · Patients with presumed drug‐sensitive TB
1 finding from 1 review